Prophylactic Methylprednisolone for Renal Protection in Cardiac Surgeries With Cardiopulmonary Bypass
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAin Shams University
About this trial
The aim of the planned study is to assess the prophylactic effect of intraoperative administration of a single dose of methylprednisolone 2 (mg/kg) in decreasing the incidence of postoperative acute kidney injury after cardiac surgeries with cardiopulmonary bypass.
Eligibility criteria
Qualifiers
Age 18-65 years.
Sex: Both sexes.
Patients with American Society of Anesthesiologists (ASA) score III-IV.
Patients scheduled for any kind of elective cardiac surgical procedure requiring cardiopulmonary bypass (e.g., coronary artery bypass grafting (CABG), valve repair/replacement, or combined procedures (
Disqualifiers
Declining to give written informed consent.
History of allergy to the medications used in the study.
Diabetic patients with HbA1C >6.5
Moderate to severe hepatic diseases (Child B-C)
Trial design
Treatments tested in this trial
- Methylprednisolone group
Treatment groups
170 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov